Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

IGM Biosciences, Inc. - Common Stock (NQ:IGMS)

1.365 +0.075 (+5.81%)
Streaming Delayed Price Updated: 1:31 PM EDT, Jun 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about IGM Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at Three Upcoming Investor Conferences
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the Jefferies Healthcare Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Refocusing of Sanofi Collaboration
Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseases 
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Third Quarter 2023 Financial Results
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at Two Upcoming Investor Conferences
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Second Quarter 2023 Financial Results
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Announces Proposed Public Offering and Concurrent Private Placement
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the Jefferies Healthcare Conference
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
Imvotamab, a CD20 x CD3 bispecific monoclonal antibody, offers potential for deeper B cell depletion than currently approved therapies 
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at Two Upcoming Investor Conferences
From IGM Biosciences, Inc.
Via GlobeNewswire
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
From IGM Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.